Expert Ratings for Travere Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. The analysts have an average price target of $24.75 versus the current price of Travere Therapeutics at $7.62, implying upside. This current average has decreased by 17.5% from the previous average price target of $30.00.
September 22, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts predict an upside for Travere Therapeutics with an average price target of $24.75, which is significantly higher than its current price of $7.62. However, the average price target has decreased by 17.5% from the previous target of $30.00.
The analysts' average price target for Travere Therapeutics is significantly higher than its current price, indicating a potential upside. However, the decrease in the average price target could suggest that analysts are becoming less optimistic about the stock's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100